Skip to content
Head to head

Novavax vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: NVAX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

NVAX +9.9%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
NVAXVRTX
Snapshot
Sector--Biotechnology
Last price7.47515.02
Change today-3.24%-1.08%
1-year return+20.1%+22.0%
Market cap$1.23B$130.58B
52-week range6.36 – 13.39412.27 – 568.67
Valuation
P/E (TTM)-14.3733.14
P/E percentile, own 5-yr range5th99th
P/B-5.686.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.5815.32
Net profit (TTM)$425.72M$3.88B
Revenue (TTM)$411.65M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-3.0%+11.8%
Gross margin78.0%85.5%
Operating margin-21.0%33.1%
Net margin-18.6%30.7%
Free cash flow (TTM)$-244.08M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership68.4%96.8%
Insider activity (12mo)41 buy / 6 sell28 buy / 22 sell
Short interest (% of float)28.1%1.9%
Analyst consensus60% buy / 40% sell (5)95% buy / 5% hold (21)
Analyst price target$14 (+82%)$624 (+21%)
StockVane view
StockVane Quant RatingD (62)C (68)
Company
Employees7496,400
Founded19871989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.